Systematic review on evidence of the effectiveness of cholesterol-lowering drugs

Advances in Therapy

Volumn 27, Issue 6, 2010, Pages 348-364

  Gupta, Abhaya ^a   Guyomard, Veronique ^b   Zaman, M Justin S ^c   Rehman, Habib U ^d   Myint, Phyo Kyaw ^e  

^a WEST WALES GENERAL HOSPITAL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d REGINA QU APPELLE HEALTH REGION   (Canada)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterollowering drugs; Coronary heart disease; Hypercholesterolemia; Risk

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; CHOLESTEROL; COLESTYRAMINE; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FUROCOUMARIN; GEMFIBROZIL; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SITOSTANOL; UNINDEXED DRUG; AZETIDINE DERIVATIVE; PHYTOSTEROL;

AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEVELOPING COUNTRY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GRAPEFRUIT JUICE; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE; LIVER DISEASE; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MEDITERRANEAN DIET; MEDLINE; MORTALITY; MUSCLE CRAMP; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK MANAGEMENT; SIDE EFFECT; STOMACH IRRITATION; STOMACH PAIN; SYSTEMATIC REVIEW; URBANIZATION; URIC ACID BLOOD LEVEL; URTICARIA; COMPLICATION; CORONARY DISEASE; DRUG COMBINATION; EVIDENCE BASED PRACTICE; PATIENT SELECTION; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTYRAMINE RESIN; CORONARY DISEASE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED PRACTICE; FATTY ACIDS, OMEGA-3; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; NIACIN; PATIENT SELECTION; PHYTOSTEROLS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 77956230175     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0033-6     Document Type: Review

References (109)

1. DOH web site. Coronary heart disease. Policy and guidance. London: Department of Health. Available at: Http://www.dh.gov.uk/PolicyAndGuidance/ HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Last accessed February 24, 2010.
2. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
3. Verschuren WMM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long term coronary heart disease mortality in different cultures: Twenty five year follow up of the Seven Country Study. JAMA. 1995;274:131-136.
4. American Heart Association, National Heart, Lung, and Blood Institute. The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721-1733.
5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. Wood D. Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. JBS-2. Heart. 2005;91(suppl. V):1-2.
8. Brown MS, Faust JR, Goldstein JL. Inhibition of 3-hydroxy 3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 1978;253:1121-1128.
9. Brown MS, Goldstein GL. A receptor mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
10. Berglund LF, Beltz WF, Elam RL, Witztum JL. Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. J Lipid Res.1994;35:956-965.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: Systematic review and meta-analysis. BMJ. 2003;326:1423.
12. Chong PH, Kezele R, Franklin C. High-density lipoprotein cholesterol and the role of statins. Circ J. 2002;66:1037-1044.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Society of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
15. La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
16. Nissen S, Nicholls S, Siphai I, et al. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA. 2006;295:1556-1565.
17. Takemoto M, Liao JK. Pleotropic effects of 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vas Biol. 2001;21:1712.
18. Gylling H, Miettinen TA. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis. 2002;160:477-478.
19. Olsson AG, Eriksson M, Johnson O, et al. A 52- week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target (3T) study. Clin Ther. 2003;25:119-138.
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLA.R.* Trial). Am J Cardiol. 2003;92:152-160.
21. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia - the CURVES study. Am J Cardiol. 1998;81:582-587.
22. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin related adverse events: A meta-analysis. Clin Ther. 2006;28:26-35.
23. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin induced myopathy - a genomewide study. N Engl J Med. 2008;8:789-799.
24. Kane GC, Lipsky JJ. Drug grapefruit juice interactions. Mayo Clin Proc. 2000;75:933-942.
25. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative Simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA. 2004;292:1307-1316.
26. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalised rhabdomyolysis in patients treated with lipid lowering drugs. JAMA. 2004;292:2585-2590.
27. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A meta-analysis. JAMA. 2006;295:74-80.
28. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis and cancer: Insights from large randomised statin trials. J Am Coll Cardiol. 2007;50:409-418.
29. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40(suppl. 1):S53-S58.
30. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
31. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
32. Rubins, Bloomfield H, Davenport J, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-2833.
33. [No authors listed]. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The BIP study. Circulation. 2000;102:21-27.
34. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between LDL particle size, plasma lipoproteins and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DIAS). Circulation. 2003;107:1733-1737.
35. FIELD Study Investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) randomised controlled trial. Lancet. 2005;366:1849-1861.
36. Kind AH, Zakowski LJ, McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: An uncommon but serious adverse reaction. WMJ. 2002;101:53-56.
37. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
38. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171:87-96.
39. Canner PL, Berge KG, Wenger N, et al. Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
40. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
41. Grundy SM, Vega GI, McGovern MI, et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568-1576.
42. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann- Pick C1 like 1 regulates biliary cholesterol concentration and is target of ezetimibe. J Clin Invest. 2007;117:1968-1978.
43. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741.
44. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of potent new selective cholesterol absorption inhibitor, ezetimibe in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-1097.
45. Thomsen AB, Hasen HB, Christiansen C, Green H, Berger A. Effect of free plant sterols in low-fat milk on serum lipid profile in hypercholesterolemic subjects. Eur J Clin Nutr. 2004;58:860-870.
46. Patch CS, Tapsell LC, Williams PG. Plant sterol/stanol prescription is an effective treatment strategy for managing hypercholesterolemia in outpatient clinical practice. J Am Diet Assoc. 2005;105:46-52.
47. Plat J, Mensink RP. Plant stanol and sterol esters in the control of blood cholesterol levels: Mechanism and safety aspects. Am J Cardiol. 2005;96:15-22.
48. Kreisberg RA, Oberman A. Medical management of hyperlipidemia/ dyslipidemia. J Clin Endocrinol Metab. 2003;88:2445-2461.
49. Yashodhra BM, Umakanth S, Pappachan JH. Omega 3 fatty acids: A comprehensive review of their role in health and disease. Postgrad Med J. 2009;85:84-90.
50. Hu BF, Brouner L, Willet W. Fish and omega 3 fatty acids intake and risk of coronary heart disease in women. JAMA. 2002;287:1815-1821.
51. Albert C, Hennekem CH, O'Donnell C, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23-28.
52. Marchioli R, Barzi F, Bomba E, et al. GISSI Prevenzione Investigators. Early protection against sudden death by polyunsaturated fatty acids after myocardial infarction. Circulation. 2002;105:1897-1903.
53. Yokoyama H, Origasa H, Matsuzaki M, et al. JELIS Investigators. Effects of EPA on major coronary events in hypercholesterolemic patients. Lancet. 2007;369:1090-1098.
54. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of O3FA for mortality, cardiovascular disease and cancer: Systematic review. BMJ. 2006;333:752-760.
55. Hooper L, Thompson RL, Harrison RA, et al.Omega 3 fatty acids for prevention and treatment of CVD. Cochrane Database Syst Rev. 2004;(4):CD003177.
56. Mozaffarian D, Rimm EB. Fish intake, contaminants and human health: Evaluating risks and benefits. JAMA. 2006;296:1885-1899.
57. Gapinski JP, Van Ruiswyk JV, Hendebert GR, et al. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med. 1993;153:1595-1601.
58. Lee IM, Cook NR, Gaziana JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Womens Health Study: A randomised controlled trial. JAMA. 2002;288:322-333.
59. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HERS research group. JAMA. 1998;280:605-613.
60. Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Womens Health Initiative RCT. JAMA. 2002;288:321-333.
61. Estruch R, Martinez-Gonzalez MA, Corella D, et al. PREDMED Study investigators. Effects of Mediterranean style diet on cardiovascular risk factors: A randomised trial. Ann Intern Med. 2006;145:1-11.
62. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors and rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation. 1999;99:779-785.
63. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronised fenofibrtae alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198-1202.
64. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
65. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin and fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462-468.
66. Davidson MH. Reducing residual risk for patients on statin therapy: The potential role of combination therapy. Am J Cardiol. 2005;96:3K-13K.
67. The ACCORD Investigators. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
68. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
69. Taylor AJ, Sullenberger LE, Lee HJ. Arterial Biology for the Investigation of the Treatment Effects of Cholesterol (ARBITOR-2): A double blind placebo controlled study of extended release niacin in atherosclerosis progression in secondary prevention. Patients treated with statins. Circulation. 2004;110:2-7.
70. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended release niacin on carotid intima-media thickness (ARBITER-3). Curr Med Res Opin. 2006;22:2243-2250.
71. Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.
72. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134.
73. Goldberg AC, Sapre A, Liu L, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620-629.
74. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid altering efficacy of ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041-2053.
75. Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER study investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease - results from EXPLORER study. Am J Cardiol. 2007;99:673-680.
76. Denke M, Pearson T, McBride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006;3:393-102.
77. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins. Int J Clin Pract. 2004;58:746-755.
78. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
79. Rossebo AB, Pederson TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
80. Peto R, Emberson J, Landray M, et al. Analysis of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357-1366.
81. Taylor AJ, Villimes TC, Stanek EJ, et al. Extended release niacin or ezetimibe and carotid intima media thickness. N Engl J Med. 2009;361:2113-2122.
82. Kastelein JP, Bots ML. Statin therapy with ezetimibe or niacin in high risk patients. N Engl J Med. 2009;361:2180-2183.
83. Stamler J, Wentworth D, Neaton JD. Is the relation between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
84. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol levels. BMJ. 1991;303:276-282.
85. Wilson PW, Anderson KM, Castelli WP. Twelve year incidence of CHD in middle aged adults during the era of hypertensive therapy. The Framingham Offspring Study. Am J Med. 1991;90:276-282.
86. Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): Results of follow up at 8th years. Eur Heart J. 1998;19(suppl. A):A2-A11.
87. Verschuuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different culture: Twenty five year follow up of the seven countries study. JAMA. 1995;274:131-136.
88. Rifkind BM. Lipid research clinics coronary primary prevention trial: Results and implications. Am J Cardiol. 1984;54:30C-34C.
89. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
90. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
91. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
92. Ridker P, Danielson E, Francisco AH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med. 2008;359:2195-2207.
93. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments. J Am Coll Cardiol. 2008;52:1769-1781.
94. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
95. Sachs FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trials Investigators. CARE. N Engl J Med. 1996;335:1001-1009.
96. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: A systemic review. Arch Intern Med. 2005;165:725-730.
97. James H, O Keefe Jr. Optimal LDL is 50-70 mg/dL. Lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:11.
98. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405-1410.
99. NHS web site. The information centre for health and social care. Prescriptions dispensed in the community 1996-2006 [NS]. Department of Health. Available at: Http://www.ic.nhs.uk/statisticsand- data-collections/primary-care/ prescriptions/prescriptions-dispensed-in-the-community-1996- 2006-%5Bns%5D. Last accessed February 24, 2010.
100. NICE web site. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: Http://guidance.nice.org.uk/CG67. Last accessed February 24, 2010.
101. Unwin N, Thomson R, O'Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: Cross sectional study of cardiovascular disease and risk factors. BMJ. 1998;317:1125-1130.
102. Cullen P, Schulte H, Assman G. The Munster Heart Study. Total mortality in middle aged men is increased at low total and LDL-C concentration in smokers but not in nonsmokers. Circulation. 1997;96:2128-2136.
103. Helaine E, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care. 2003;26:861-867.
104. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative research group. The antihypertensive and lipid lowering treatment for prevention of heart attack trial: Major outcomes in moderately hypercholesterolemic hypertensive patients randomised to pravastatin or usual care. ALLHAT-LLT. JAMA. 2002;288:2998-3007.
105. Farmer JA, Gotto AM Jr. The HPS: Expanding the boundaries for high risk coronary disease prevention. Am J Cardiol. 2003;92:31-91.
106. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002; 360:1623-1630.
107. Afilalo J, Gustavo Duque, Steele R. Statins for secondary prevention in elderly patients - a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45.
108. McKeigue P M, Miller G J, Marmot MG. Coronary heart disease in South Asians overseas: A review. J Clin Epidemiol. 1989;42:597-609.
109. Spriston K, Primatesta P, eds. Risk Factors for Cardiovascular Disease. Health Survey for England 2003. Vol. 2. London: The Stationery Office; 2004.